ArticleFrontiers in immunology2021
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Review
- Disruption of circadian rhythms and behavior in Drosophila melanogaster induced by Epstein-Barr virus: insights into viral infections and host physiology.Behavioral and brain functions : BBF · 2025Article
- The Relevance of Experimental Models in Assessing the Impact of Oxidative Stress on Intestinal Pathology.Journal of clinical medicine · 2025Review
- Toll-like Receptor 9 Mediates Epstein-Barr Virus-Aggravated Inflammation in a Mouse Model of Inflammatory Bowel Disease.Biomedicines · 2025Article
- In vivo and in vitro pathogenicity of Fusarium oxysporum and its biofilm components.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Article
- The Effects of Endosomal Toll-like Receptor Inhibitors in an EBV DNA-Exacerbated Inflammatory Bowel Disease Mouse Model.Viruses · 2024Article
- An IL-17A-centric response to Epstein-Barr virus DNA mediated by dendritic Cell-T cell interactions.Frontiers in molecular biosciences · 2024Article
- Animal models of inflammatory bowel disease: category and evaluation indexes.Gastroenterology report · 2024Review
- Effect and mechanism of total ginsenosides repairing SDS‑inducedExperimental and therapeutic medicine · 2023Article
- Silibinin alleviates intestinal inflammation via inhibiting JNK signaling inFrontiers in pharmacology · 2023Article
- Review
- UsingFrontiers in pharmacology · 2022Review
- Epstein-Barr Virus DNA Exacerbates Colitis Symptoms in a Mouse Model of Inflammatory Bowel Disease.Viruses · 2021Article
- Effect of Epstein-Barr Virus DNA on the Incidence and Severity of Arthritis in a Rheumatoid Arthritis Mouse Model.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The Epstein-Barr virus (EBV) commonly infects humans and is highly associated with different types of cancers and autoimmune diseases. EBV has also been detected in inflamed gastrointestinal mucosa of patients suffering from prolonged inflammation of the digestive tract such as inflammatory bowel disease (IBD) with no clear role identified yet for EBV in the pathology of such diseases. Since we have previously reported immune-stimulating capabilities of EBV DNA in various models, in this study we investigated whether EBV DNA may play a role in exacerbating intestinal inflammation through innate immune and regeneration responses using the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.